TY - JOUR
T1 - Associations between a patient-reported outcome (PRO) measure of sarcopenia and falls, functional status, and physical performance in older patients with cancer
AU - Gewandter, Jennifer S.
AU - Dale, William
AU - Magnuson, Allison
AU - Pandya, Chintan
AU - Heckler, Charles E.
AU - Lemelman, Tatyana
AU - Roussel, Breton
AU - Ifthikhar, Rafa
AU - Dolan, James
AU - Noyes, Katia
AU - Mohile, Supriya G.
N1 - Funding Information:
We'd like to thank the staff (Terri Lloyd) that administers the geriatric assessments at the SOCARE clinic for generously allowing us to use their data. This work was funded by the National Institute on Aging , the National Cancer Institute , and the Patient Centered Outcomes Research Institute ( R03 AG042342 , U10CA37420 , and R01 CA177592 ). The work was also funded by the Susan H Green Memorial Grant and Hartford Foundation pilot grant (to Magnuson) and by the philanthropic donation of Sandy Lloyd to the Geriatric Oncology Program at the James Wilmot Cancer Institute, as well as by grant 1 K24 RR024198-02 from the National Heart Lung and Blood Institute (J. Dolan's time). We would also like to thank the patients whose data were used for this study.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015
Y1 - 2015
N2 - Objective: In older patients with cancer, we aimed to investigate associations between a patient-reported outcome measure for sarcopenia (SarcoPRO) and the Short Physical Performance Battery (SPPB), self-reported falls, and limitations in instrumental activities of daily living (IADLs). Materials and Methods: Assessments were conducted as part of the initial evaluation of older, often frail, patients with cancer seen in the Specialized Oncology Care and Research in the Elderly (SOCARE) clinic. Univariate associations were evaluated using Spearman's correlation and Wilcoxon sign ranked tests. Logistic regressions were used to identify associations of clinical factors and SarcoPRO scores or SPPB scores with falls and IADL limitations. Results: In total, 174 older patients with cancer were evaluated. A moderate correlation was found between the SarcoPRO and the SPPB (ρ = 0.62). After adjusting for multiple clinical factors, neither the SarcoPRO nor the SPPB were associated with falls. In contrast, both higher SarcoPRO (i.e., worse) and lower SPPB (i.e., worse) scores were associated with limitations in IADLs (odds ratio for one unit change in predictor: SarcoPRO: 1.06, p < 0.0001; SPPB: 0.71, p = 0.003, respectively). Models using the SarcoPRO and SPPB explained similar amounts of variability in association with IADL limitations (AUC: 0.88 vs. 0.87, respectively). Conclusions: The SarcoPRO was moderately associated with the SPPB, an objective measure of physical performance, and was associated with limitations in IADLs. Thus, older patients with cancer who present with IADL limitations should be screened for sarcopenia. The SarcoPRO shows promise as a measure for screening as well as outcome assessment for research on sarcopenia.
AB - Objective: In older patients with cancer, we aimed to investigate associations between a patient-reported outcome measure for sarcopenia (SarcoPRO) and the Short Physical Performance Battery (SPPB), self-reported falls, and limitations in instrumental activities of daily living (IADLs). Materials and Methods: Assessments were conducted as part of the initial evaluation of older, often frail, patients with cancer seen in the Specialized Oncology Care and Research in the Elderly (SOCARE) clinic. Univariate associations were evaluated using Spearman's correlation and Wilcoxon sign ranked tests. Logistic regressions were used to identify associations of clinical factors and SarcoPRO scores or SPPB scores with falls and IADL limitations. Results: In total, 174 older patients with cancer were evaluated. A moderate correlation was found between the SarcoPRO and the SPPB (ρ = 0.62). After adjusting for multiple clinical factors, neither the SarcoPRO nor the SPPB were associated with falls. In contrast, both higher SarcoPRO (i.e., worse) and lower SPPB (i.e., worse) scores were associated with limitations in IADLs (odds ratio for one unit change in predictor: SarcoPRO: 1.06, p < 0.0001; SPPB: 0.71, p = 0.003, respectively). Models using the SarcoPRO and SPPB explained similar amounts of variability in association with IADL limitations (AUC: 0.88 vs. 0.87, respectively). Conclusions: The SarcoPRO was moderately associated with the SPPB, an objective measure of physical performance, and was associated with limitations in IADLs. Thus, older patients with cancer who present with IADL limitations should be screened for sarcopenia. The SarcoPRO shows promise as a measure for screening as well as outcome assessment for research on sarcopenia.
KW - Falls
KW - IADLs
KW - Patient reported outcome measure
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=84941701900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941701900&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2015.07.007
DO - 10.1016/j.jgo.2015.07.007
M3 - Article
C2 - 26365897
AN - SCOPUS:84941701900
SN - 1879-4068
VL - 6
SP - 433
EP - 441
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 6
ER -